Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 0.42 |
| ▸ | HTR2C | P28335 | 17/20 | 0.42 |
| ▸ | HTR2B | P41595 | 17/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6855304 | 1.00 | HTR2A (0.42) | HTR2AHTR2CHTR2BKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2896840 | 0.98 | KDM4E (0.42) | HTR2AHTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL29327258 | 0.77 | PLD1 (0.47) | HTR2AHTR2CHTR2BALDH1A1CHRNB2 | |
| SCHEMBL16933653 | 0.76 | HCRTR1 (0.44) | HTR2AHTR2CHTR2B | |
| SCHEMBL16933651 | 0.76 | HCRTR1 (0.44) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL29731417 | 0.76 | HTR2A (0.34) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL30777531 | 0.75 | ROCK2 (0.42) | HTR2AHTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL23744679 | 0.74 | HTR2A (0.46) | HTR2AHTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL31713174 | 0.74 | HTR2A (0.46) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL26087038 | 0.74 | HTR2A (0.46) | HTR2AHTR2CHTR2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797824-B2 | UEFUL IN THE DIAGNOSIS AND THERAPY OF AFFECTIVE DISORDERS SUCH AS SCHIZOPHRENIA AND DEPRESSION AS WELL AS CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM | NEUROGEN CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE | 2003-01-23 | — | — | US | disclosed |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-6358955-B1 | SCHIZOPHRENIA, PSYCHOLOGICAL DISORDERS, PARKINSON*S DISEASE; ANTIDEPRESSANTS | NEUROGEN CORPORATION | 2002-03-19 | — | — | US | disclosed |
| US-6069251-A | HIGHLY SELECTIVE PARTIAL AGONISTS OR ANTAGONISTS AT BRAIN DOPAMINE RECEPTOR SUBTYPES OR PRODRUGS; DIAGNOSIS AND TREATMENT SCHIZOPHRENIA; ANTIDEPRESSANTS; CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM. | NEUROGEN CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
| US-5712392-A | DOPAMINERGIC AGENTS TREATING SCHIZOPHRENIA, ANTIDEPRESSANTS FOR PARKINSON'S DISEASE | NEUROGEN CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| US-5656762-A | TREATING SCHIZOPHRENIA, DEPRESSION, PARKINSON*S DISEASE | NEUROGEN CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646281-A | FOR USE IN THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA, DEPRESSION AND PARKINSON*S DISEASE | NEUROGEN CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5633377-A | DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSON'SDISEASE | NEUROGEN CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | CHRNA4, GRIA4, OPRM1 | HTR2A 58/4885HTR2C 10/4885HTR2B 55/4885 |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | DRD2, OPRM1, OPRD1 | HTR2A 16/4885HTR2C 7/4885HTR2B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.